The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension☆
Section snippets
Material and methods
Patients were included in this study if they demonstrated the following criteria: 18 years of age or older; willingness to comply with the investigator’s and protocol’s instructions; a clinical diagnosis of primary open-angle, pigment dispersion, or exfoliation glaucoma, or ocular hypertension in at least one eye (study eye); at baseline (visit 2) an intraocular pressure at the 08:00 hour between 22 and 34 mm Hg in the study eye(s); and a visual acuity of 20/200 or better in the study eye(s).
Results
Thirty-three patients were randomized and completed this trial. The characteristics of patients included in this study are found in Table 1.
The mean intraocular pressures for each time point in this study are shown in Figure 1 for baseline and both active treatments. For brimonidine, there was a statistical reduction from baseline for the diurnal curve as well as each time point, except hours 10 and 12 (P = .14 and P = .21, respectively). The range of the mean pressure reduction over the
Discussion
Latanoprost was released commercially by Pharmacia, Inc, in 1996 as an ocular hypotensive agent. Latanoprost is an analog of an F2α prostaglandin and is highly selective for the F prostanoid receptor.6 Several studies have indicated that the mechanism of action of the intraocular pressure reduction by latanoprost is increased uveoscleral outflow.7, 8, 9, 10 When compared with timolol maleate given twice daily, latanoprost 0.005% once daily has demonstrated either an equal or statistically
References (31)
- et al.
Increase uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2a-1-isopropylester in the cynomolgus monkey
Exp Eye Res
(1989) - et al.
Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey
Exp Eye Res
(1989) - et al.
Prostaglandin F2a-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow
Am J Ophthalmol
(1988) - et al.
Effects of PhXA41, a new prostaglandin F2a analog, on aqueous humor dynamics in human eyes
Ophthalmology
(1993) - et al.
Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morninga comparison with timolol
Ophthalmology
(1995) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucomaa six-month, masked, multicenter trial in the United States
Ophthalmology
(1996)- et al.
A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
Ophthalmology
(1996) - et al.
Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension
Ophthalmology
(1999) - et al.
Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit
Am J Ophthalmol
(1999) Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily1-year results in glaucoma patients
Am J Ophthalmol
(1999)
Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or hypertension
Ophthalmology
A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
Surv Ophthalmol
Brimonidine tartratea one month dose response study
Ophthalmology
Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension
Surv Ophthalmol
Development and use of brimonidine in treating acute and chronic elevations of intraocular pressurea review of safety, efficacy, dose response, and dosing studies
Surv Ophthalmol
Cited by (61)
A Long-term Safety Study of Latanoprost in Pediatric Patients With Glaucoma and Ocular Hypertension: A Prospective Cohort Study
2018, American Journal of OphthalmologyCitation Excerpt :No deaths were reported during the study (data not shown in tables). While the efficacy and safety of latanoprost in adult glaucoma patients have been established in several studies,21,22 published data on the effect of long-term treatment with latanoprost in pediatric patients are limited.19,20,23,24 To our knowledge, this is the first international prospective study conducted to evaluate the real-world long-term effects of latanoprost compared to non-PG treatment on ocular development and safety in a pediatric glaucoma population.
Update on the role of alpha-agonists in glaucoma management
2011, Experimental Eye ResearchThe adrenergic system and adrenergic agonists
2009, Becker-Shaffer's Diagnosis and Therapy of the Glaucomas: Eighth EditionComparison of the 24-Hour Intraocular Pressure-Lowering Effects of Latanoprost and Dorzolamide/Timolol Fixed Combination after 2 and 6 Months of Treatment
2008, OphthalmologyCitation Excerpt :The significance level was set at 5%, and a 2-way analysis was used for all tests. This study had at least an 80% power to identify a 1.2-mmHg difference between mean diurnal pressures, assuming a standard deviation of 2.8 mmHg between treatments.13–17 Only one eye was randomly chosen to be included in the analysis.
Efficacy and Safety of Latanoprost versus Travoprost in Exfoliative Glaucoma Patients
2007, OphthalmologyCitation Excerpt :Patients who could not safely be washed out from their current glaucoma treatment or were at risk for significant glaucomatous deterioration during the study were also excluded from this trial. The methods for the present study were similar to those described previously.3,12–16 All patients completed an Institutional Review Board–approved informed consent form before any procedures were performed.
- ☆
This study was sponsored by an unrestricted grant from Pharmacia, Inc, Peapack, New Jersey.